New Prostate Cancer Immunotherapy- Prostvac

NIH meeting

Dr. Barken introduces the New Prostate Cancer Immune Therapy for earlier stages of Prostate Cancer.  Please watch the video below and see what  he learned at the National Cancer Institute recent conference mentioned above.

Dr. James Gulley explains the Prostvac approach.

Prostvac and Enzalutamide for patients who have biochemical recurrence after surgery or radiation.   copy and paste the url –

This entry was posted in Clinical Trials, Immune Therapy, Prostate Cancer, PSA, Treatments for Prostate Cancer and tagged . Bookmark the permalink.